The Corporate Law Encyclopedia

The Deal Process & Lifecycle

A private-company acquisition runs a recognizable course: confidentiality agreement, letter of intent, exclusivity, diligence, definitive agreement with disclosure schedules and consents, regulatory clearance, closing, and a post-closing tail of escrow and indemnification claims. BC 27

The confidentiality agreement (NDA) is generally the first contract signed. BC 33 The buyer needs information to decide whether to bid; the target needs its trade secrets protected and, often, the existence of the talks kept quiet. The load-bearing pieces are the definition of confidential information, the use restriction (evaluation of a negotiated transaction only), the permitted-recipient list, and the standard exceptions (public information, prior possession, third-party receipt, independent development).

Two provisions punch above their weight: the compelled-disclosure carve-out, which should require prompt notice and limit disclosure to what is legally compelled, and any residuals clause, which lets the recipient use what its people remember and can quietly swallow the whole agreement. BC 35, 275 Targets of public-company deals should expect to be asked for a standstill; competitor deals may need phased disclosure so the most sensitive data moves last. BC 36

The letter of intent is usually non-binding as to deal terms but exists to make a few provisions binding early, classically the no-shop and control of publicity, and to start the Hart-Scott-Rodino clock. Its hazards are real: a signed LOI is hard to keep confidential, can create a duty to negotiate in good faith a court will enforce, and may hand one side negotiating leverage. A term sheet trades away the binding provisions for speed, since it is typically unsigned. BC 35–36 An exclusivity agreement buys the buyer a negotiating window in which the target cannot shop the deal.

Due diligence runs from the request list through the data room and feeds everything downstream: the price, the representations the buyer demands, the disclosure schedules the target writes, and the consents that become closing conditions. One classic diligence task is reviewing the target's contracts for anti-assignment and change-of-control clauses, because which clauses are triggered depends on the deal structure chosen (see Deal Structures & Tax).

Signing and closing usually separate. The gap exists to clear HSR, gather consents, hold any stockholder vote, and arrange financing; a simultaneous sign-and-close, possible mainly in private deals, deletes the pre-closing covenants, closing conditions, and termination provisions wholesale. BC 42 After closing come the payments with a tail: escrow, earn-outs, noncompetes, and indemnification claims, ending at escrow release. BC 27

Watch for

The LOI question is never "binding or not" but which provisions bind. And diligence is not a box-check: in stock-consideration deals it runs both ways, since the target's stockholders are buying the acquirer's paper. BC 13

See also: Anatomy of the Agreement, Regulatory Gates, Public M&A.

Due Diligence

Due diligence is the buyer's investigation of what it is about to buy, and it is the hub of the deal: its findings set the price, dictate the representations the buyer demands, fill the disclosure schedules, and turn into closing conditions, special indemnities, or a decision to walk.

The mechanics are simple in shape. The buyer sends a diligence request list; the target populates a virtual data room with its corporate records, financials, contracts, and the rest; and the parties run a question-and-answer process as gaps appear. The early task introduced in the deal process, reading the target's contracts for anti-assignment and change-of-control clauses, is one thread of a much larger investigation, because which of those clauses fire depends on the structure chosen.

The work runs in parallel workstreams, usually staffed by specialists. Corporate confirms the target is validly organized and that its capitalization (the cap table) is what the seller says it is. Financial and accounting diligence, often a quality-of-earnings study by an accounting firm, tests whether reported EBITDA is real and recurring, which feeds straight into valuation. Tax hunts for exposures and confirms the structure's assumptions. Commercial contracts reads the material agreements for assignment, change-of-control, exclusivity, and termination triggers. Intellectual property verifies ownership and screens open-source use; employment and benefits covers the workforce and ERISA plans; litigation sizes the disputes; regulatory and compliance checks licenses, anti-corruption, and sanctions; and environmental, real estate, insurance, and data-privacy/cybersecurity round out the standard set.

The output is not a pile of documents but a set of judgments: diligence memos by workstream and a red-flag report that surfaces the issues that change the deal. Each red flag has a small menu of responses. Reprice it, when it is a value problem. Demand a specific representation so the risk is covered by the indemnity. Push it onto the disclosure schedule so the seller owns it. Turn a needed third-party consent into a closing condition. Carve it out as a special indemnity with its own escrow. Or, if it is bad enough, walk. Diligence is the engine that makes every later entry in this Part necessary.

Two refinements matter. In stock-consideration deals diligence runs both ways, because the target's stockholders are accepting the buyer's paper and must investigate the buyer in turn. And diligence does not stop at signing: confirmatory diligence continues through the gap to closing, and where antitrust-sensitive information must change hands, counsel set up clean teams so competitors never see each other's commercial secrets before the deal is cleared.

Watch for

Diligence is only as good as the data room and the questions asked of it; a thin data room is itself a finding. Mind privilege when circulating findings, and remember that what the buyer learns can cut against it later: a buyer that discovers a problem and closes anyway walks straight into the sandbagging question.

See also: The Deal Process, Valuation, Representations & Warranties, Indemnification.

Valuation & Fairness Opinions

Before there is a price there is a value, and value is triangulated, not calculated: comparable companies, precedent transactions, and a discounted-cash-flow model, cross-checked against what a financial buyer could pay and what the deal does to the buyer's own earnings, and finally blessed by a fairness opinion.

Start with the unit of measure. A company's equity value is what its shares are worth; its enterprise value adds net debt and is what the whole operating business costs to own, equity value plus debt minus cash. Multiples are quoted on enterprise value for capital-structure-neutral measures like EBITDA and revenue, and on equity value for bottom-line earnings (the price/earnings ratio). Getting this bridge right is the first discipline of valuation, and the reason the structure and tax entry can already speak in those terms.

The three core lenses each carry a built-in bias worth knowing. Comparable companies ("trading comps") value the target against the public-market multiples of similar listed firms; because those are minority, day-to-day trading prices, they carry no control premium. Precedent transactions value it against the multiples actually paid in past acquisitions of similar targets; because buyers pay for control and synergies, transaction multiples run higher, commonly a 20 to 40 percent control premium above trading levels. Discounted cash flow leaves the market aside and values the business intrinsically, projecting its free cash flows and discounting them at a weighted-average cost of capital to a present value plus a terminal value. The empirical pattern, documented in Damodaran's NYU data, is that comps and precedents tend to bracket the DCF, with precedents sitting above trading comps by roughly the control premium and expected synergies.

Two further analyses sit alongside the core three. An LBO analysis asks what a financial buyer could pay and still hit its target return given available leverage; it sets a practical floor under an auction. An accretion/dilution analysis is the buyer-specific test in a stock or mixed deal: combine the two companies' earnings and the new shares issued, and see whether pro-forma earnings per share rise (accretive) or fall (dilutive). It speaks to the acquirer's optics rather than to the value exchanged, but it moves boardrooms.

The capstone is the fairness opinion: a letter from the board's financial adviser stating that the consideration is "fair, from a financial point of view" to the relevant holders. It is as much a product of process as of math. The lesson of Smith v. Van Gorkom was that a board must inform itself before approving a sale (see Fiduciary Duties), and the opinion is how a public board shows that it did. It is not a valuation, not a recommendation, and not a promise that the price is the highest possible; and because the bank that opines may also earn a success fee or provide the buyer's financing, FINRA Rule 5150 requires the opinion to disclose those conflicts.

Watch for

Every model is only as good as its inputs: a DCF is a precise-looking number built on guessed projections, and a comp set quietly chosen to flatter the price will do exactly that. Watch the conflicted adviser whose stapled financing or success fee colors the opinion, and read precedent multiples for the cycle they came from; deals struck at the top of a market are not "market" at the bottom.

See also: Purchase Price & Consideration, Deal Structures & Tax, Private Equity, Fiduciary Duties & the Sale Process.

Deal Structures & Tax

Five canonical structures acquire a private business: stock purchase, asset purchase, and three mergers (straight forward, forward subsidiary, reverse subsidiary). The choice is driven by approvals, liabilities, consents, taxes, and what the buyer actually wants to own. BC 16–21

Start with how deals differ at all: public or private target, strategic or financial buyer, cash or stock consideration, leveraged or not. BC 8–9 A target's equity value is the value of its outstanding equity; its enterprise value adds debt and subtracts cash, what the whole business costs to own. A target with 100m shares at $50, $3b of debt and $0.5b of cash has a $5b equity value and a $7.5b enterprise value. BC 11 Strategic buyers are operating companies that may pay in stock and may keep management; financial buyers are PE-sponsored shell entities that pay cash, lever the deal, and almost always keep and re-incentivize management. BC 12

The structures, in brief. BC 30–32 A stock purchase buys 100% of the target's shares from its stockholders directly; every stockholder must sign, the target becomes a wholly-owned subsidiary, all liabilities come along indirectly, and contracts are not assigned (though change-of-control clauses may still fire).

An asset purchase buys assets and specified liabilities from the company; majority stockholder approval suffices for a sale of substantially all assets, unwanted liabilities can be left behind, but contracts and permits must be assigned, transfer taxes can apply, and bulk-transfer and fraudulent-transfer rules lurk.

The mergers are statutory combinations on majority approval: in the straight forward merger the target merges into the buyer; in the forward-subsidiary merger into a new merger sub; in the reverse-subsidiary merger, the workhorse of private M&A, the merger sub merges into the target, which survives as the buyer's subsidiary, so contracts are not directly assigned and the tax treatment tracks a stock sale.

The tax fork is the heart of it, and it turns on two questions: how many times the sale is taxed, and whose asset basis the buyer ends up with. In a stock sale, the stockholders sell their shares and pay a single capital-gains tax; the buyer steps into the company and simply inherits the target's existing asset basis (its "inside" or carryover basis), so nothing is written up. In an asset sale, the same value is taxed twice, the double tax: first the corporation pays tax on the gain in its assets, then the stockholders pay again when the after-tax cash is distributed out to them. What the buyer gets for enduring that second tax is a stepped-up basis, the right to depreciate the assets from their full purchase price rather than the seller's lower historical figure, which shelters future income from tax.

The boot camp puts real numbers on it, and the comparison rewards reading line by line, because the punchline (the asset route costs the seller more but hands the buyer a larger write-off) stays invisible until you watch the two levels of tax stack up. The setup: a target owns a factory worth $100m carried at a tax basis of $80m, financed by a $70m mortgage, which leaves $30m of equity whose stock basis is $10m. Corporate tax is 21%, the individual capital-gains rate 23.8%. Both routes realize the same $20m gain, but they do not land in the same place.

Read across the bottom rows and the trade is exact. The asset sale drains roughly $3.2m more from the sellers ($22.04m versus $25.24m) because the same value is taxed twice, once at 21% inside the company and again at 23.8% on the way out. In exchange the buyer leaves with a factory it may depreciate from $100m rather than $80m, an extra $20m of future deductions. That gap is what "capturing the step-up" means, and it is why structure is a negotiation rather than an afterthought.

The negotiation over structure is therefore partly a negotiation over who captures the value of the step-up. Reverse-subsidiary mergers are taxed like stock sales; forward mergers like asset sales. BC 32 Stock consideration opens the possibility of a tax-free reorganization. BC 39

Two elections can break the link between legal form and tax result, and both exist to capture that step-up without an actual asset sale. A Section 338(h)(10) election (and its close cousin, the 336(e) election) lets the parties treat what is legally a stock sale as an asset sale for tax only: the buyer still buys shares, keeping the clean mechanics (no contracts to reassign, no liabilities to move one by one), but for tax the target is deemed to have sold its assets, so the buyer takes the same depreciable step-up the table above priced. The catch, and the reason it is negotiated rather than free, is that the deemed asset sale triggers the seller's second layer of tax; the buyer therefore grosses up the price to make the seller whole, and both sides run the numbers to see whether the step-up is worth more to the buyer than the gross-up costs. It is available only where a single owner effectively controls the whole target: an S corporation (a small, closely held company whose profits are already taxed just once, at the shareholder level, so the deemed asset sale creates no genuine double tax) or a subsidiary sold out of a consolidated group. For an ordinary standalone C corporation the election is off the table, because the second tax it would trigger is precisely the double tax the parties were trying to avoid.

When the consideration is the buyer's stock rather than cash, a different door opens: the deal can qualify as a tax-free reorganization under Section 368. "Tax-free" here means tax-deferred, not tax-forgiven: the target's stockholders pay nothing now, carry their old basis into the buyer's shares, and pay only when they eventually sell those shares. The Code recognizes several forms, distinguished by what changes hands, an "A" reorganization is a statutory merger, a "B" is a straight stock-for-stock swap, and a "C" is stock-for-assets, each with triangular variants that drop the target into a subsidiary. All of them require the sellers to keep a meaningful equity stake in the buyer under the continuity-of-interest doctrine, on the theory that a seller who rolls its investment forward into the buyer instead of cashing out has not really made a taxable "sale" yet. Two further provisions recur often enough to know by name. Section 1202 can let a founder or early investor exclude a large share, up to all, of the gain on qualified small business stock held at least five years, historically capped at the greater of $10m or ten times basis (Congress raised the dollar cap to $15m for stock acquired after mid-2025), which is why startup exit planning revolves around it. And Section 382 caps how much of a target's accumulated net operating losses the buyer may use each year after an ownership change, so a loss company's tax losses are worth less to an acquirer than their face amount, sometimes much less.

Watch for

"Less suitable for buying part of a business" is doing quiet work in the matrix: carve-outs of divisions raise their own problems, shared IP, entangled financials, transition services, that no structure solves cleanly. BC 43 And the reverse-subsidiary merger's "no assignment" advantage has edges: compare the SQL Solutions and Meso Scale decisions before promising a client that no consents are needed. BC 25

See also: Purchase Price, Regulatory Gates, Private Equity.

Purchase Price & Consideration

Price is a formula, not a number: a fixed amount, an adjustment mechanism, an earn-out, deferred paper, or the buyer's stock under an exchange ratio, and each formulation allocates risk between signing and closing differently. BC 38–40

Cash deals start from a fixed dollar amount, then layer mechanics. A purchase price adjustment trues the price up or down after closing against a benchmark, classically closing-date stockholders' equity or working capital, measured by a post-closing audit. BC 38 An earn-out pays part of the price later, contingent on the acquired business's post-closing performance; earn-outs are notoriously dispute-prone, demand careful covenants about how the buyer will run the business during the earn-out period, and, structured badly, can even constitute securities (see Regulatory Gates). BC 38, 271 Deferred payments and notes raise set-off rights, security, subordination, and installment-tax questions. BC 38–39 Part of the price typically sits in an indemnification escrow as the buyer's collection source (see Indemnification).

Stock deals price by exchange ratio, and the formulation decides who bears market risk between signing and closing. BC 45–52 Under a fixed exchange ratio (say 2 ACo shares per TCo share), the number of shares is locked, so the value delivered floats with the acquirer's stock price: target stockholders bear the downside and keep the upside. Under a fixed dollar value (floating-ratio) formulation ($300m of stock, counted at closing prices), the value is locked and the share count floats: the acquirer bears the market risk, issuing more shares as its price falls.

Worked example. A target holder is promised her value while ACo trades at $50. Under a fixed ratio of 2.0, she is locked to 2 ACo shares. If ACo slips to $40 by closing, those 2 shares are worth $80, not the $100 she expected, so she absorbs the drop (and would have kept the gain had ACo risen). Under a fixed $100 value, she instead receives whatever number of shares is worth $100 at closing, which at $40 is 2.5 shares: her value is protected, but ACo issues half a share more than the 2.0 base, and ACo's existing holders absorb that extra dilution. Same deal, opposite risk-bearer, which is the entire point of the collar fight below.

Collars split the difference by bounding the ratio or the value between agreed stock-price bands, often with walk rights if the price exits the collar. BC 48–50 Closing-price measurement is commonly an average, e.g. a 20-trading-day VWAP-style window, to blunt single-day spikes. BC 46

Watch for

In a fixed-ratio deal a falling acquirer means target holders arrive at closing with less than they priced; in a fixed-value deal a falling acquirer means existing acquirer holders eat unexpected dilution. Every collar negotiation is really an argument about which side's stockholders absorb a move in the market.

See also: Deal Structures & Tax, Indemnification, Securities-Law Foundations.

Acquisition Financing

Most acquisitions are paid for partly with borrowed money, and the central problem is certainty: the seller will not sign a deal that can collapse because the buyer's banks got cold feet, so the law of acquisition financing is mostly about closing the gap between the buyer's promise to pay and the lenders' promise to fund.

The sources stack in a predictable order. A strategic buyer may pay from balance-sheet cash or issue its own stock. A financial buyer funds an equity check from its fund, often topped up by rolled equity from management, and layers debt on top: a syndicated term loan, a high-yield bond, or a bridge facility meant to be refinanced after closing (the mechanics of that debt live in Lending & Finance and High-Yield Covenants). The more leverage, the more the deal's certainty depends on the debt package holding.

That certainty is engineered before signing through a debt commitment letter (with its companion fee letter), in which the lenders commit to provide the financing on agreed terms. The danger is the letter's conditions: if the banks can refuse to fund for reasons outside the buyer's control, the seller has signed a deal with a trapdoor. The market answer is "SunGard" conditionality, named for the 2005 leveraged buyout that standardized it, the American cousin of the London market's "certain funds" regime. Under it the conditions to funding are stripped down to mirror the conditions in the merger agreement and a short list of documentary items the buyer controls, so that if the buyer is obligated to close, the lenders are obligated to fund.

The same instinct killed the old financing condition. Before 2008, buyers routinely made closing conditional on getting their financing, an option the seller hated; after the crisis, sellers refused it, and in most strategic deals the buyer now bears financing risk outright. What replaced the condition is a pair of remedies. A reverse termination fee is a sum the buyer pays the seller if the deal dies for want of financing, often the seller's only recourse. And specific performance is usually written as conditional: the seller can force the buyer to close only if the buyer's debt financing is actually available, so the two remedies divide the world between "the money is there and you must close" and "the money is not there and you pay the fee."

One timing device ties it together: the marketing period. Lenders syndicating a large loan need a guaranteed, uninterrupted window, with current target financials in hand, to sell the debt before the buyer is forced to close. The merger agreement builds that window in, and a buyer is not obligated to close until it has run. Get the marketing period, the financial-statement requirements, and the outside date out of sync and the carefully built certainty unravels.

Watch for

The thing to police is the gap between the merger agreement's conditions and the financing's conditions: any condition in the commitment letter that is not also in the merger agreement is a hole through which the financing, and the deal, can escape. And read the reverse termination fee against the specific-performance clause as one instrument, since together they, not the buyer's good intentions, determine what the seller actually gets if the banks walk.

See also: Purchase Price & Consideration, Covenants & Closing Conditions, Private Equity, Lending & Finance.

Anatomy of the Acquisition Agreement

Every definitive acquisition agreement has the same skeleton: parties and definitions, what is being bought, the price, two sets of representations, two sets of covenants, closing mechanics and conditions, termination, indemnification, and the miscellany at the back. BC 37

The architecture matters because the parts interlock. The target's representations feed three machines at once: the buyer's walk rights through the bring-down condition, the buyer's post-closing indemnification remedy, and the information-forcing function of the disclosure schedule, the document where the target lists the exceptions to its representations and, in doing so, tells the buyer what it is actually buying. BC 41, 62–63 Covenants govern conduct between signing and closing; conditions decide whether each side must show up at closing; termination provisions decide when someone may walk before the outside date; indemnification decides who pays for surprises after. The "miscellaneous" section at the back is not boilerplate to skim: third-party beneficiary clauses, governing law, forum, and the integration clause all change litigation outcomes. BC 38, 270

The best way to internalize the anatomy is to read two real agreements side by side, and the boot camp includes both: a private-target reverse-subsidiary merger agreement (Riverbed/Mazu, 2009), with a preferred-stock waterfall, working-capital adjustment, earn-out with an objection-and-arbitration procedure, escrow, and the full private rep set (capitalization, IP and open source, tax, ERISA, 280G), BC 84–161 and a public-target one-step merger agreement (Marvell/Aquantia, 2019), with option/RSU/ESPP treatment, the fiduciary-out machinery, CFIUS and HSR covenants, a proxy covenant, a D&O tail, an MAE definition with fought-over carve-outs, and specific performance with a Chancery forum. BC 162–244 The technologies differ because the remedies differ: private deals survive closing and indemnify; public deals end at closing, so everything must be policed before it. BC 10

Watch for

Order-of-operations errors. The disclosure schedule must be final before signing; reps are negotiated against the schedule, not in the abstract; and a provision's force depends on which other provisions reference it (a rep that is excluded from the bring-down, or carved out of indemnification, is a different animal than its text suggests).

See also: Representations & Warranties, Covenants & Conditions, Indemnification, Commercial Contracts & Drafting.

Representations & Warranties

Representations are the target's sworn portrait of itself. They exist to give the buyer a walk right before closing, an indemnification remedy after it, and a forcing mechanism for information in between. BC 55

The negotiation is a clash of mindsets: the buyer pays a full price and wants comprehensive assurance, with the sellers bearing the risk of the unknown; the sellers will speak only to what they know and refuse to write an insurance policy. BC 56 The reps that draw blood are the catch-alls. The no-undisclosed-liabilities rep is fought over whether it reaches beyond GAAP-accrued liabilities to contingent ones, and even the broad version protects less than buyers assume, since courts have held that "accidents waiting to happen" are not yet contingent liabilities; a buyer worried about a specific exposure should negotiate a specific indemnity instead. BC 57, 248 The full-disclosure ("10b-5") rep has the target promise its representations omit no material fact needed to make them not misleading; it is stronger than actual Rule 10b-5, because contractual indemnification needs no scienter, an innocent misstatement still pays. Sellers should treat it as anything but boilerplate. BC 57, 248–249

Qualifiers are the volume knobs. BC 59–61 Materiality qualifiers ("in all material respects," "would not reasonably be expected to have a Material Adverse Effect") soften flat statements. Knowledge qualifiers limit a rep to what the target knows, and the definition decides everything: actual knowledge only, or constructive knowledge after reasonable inquiry, imputed from a defined knowledge group. Dating a representation ("as of the date of this Agreement") stops it from being re-made at closing through the bring-down condition, which is why sellers' counsel date reps that naturally drift, like an employee list. BC 61, 254

In public deals, knowledge qualifiers matter less than practitioners think: since public reps do not survive closing, their main job is feeding the bring-down condition, and once the buyer informs the target of a problem, the target has knowledge at closing and the qualified rep fails anyway. BC 251–252

The disclosure schedule qualifies the reps with the target's listed exceptions. Who controls updates between signing and closing, and what effect an update has on walk rights and indemnification, is itself a negotiated provision. BC 62–63 A growing market alternative shifts rep risk to an insurer: rep & warranty insurance, which the Hotshot courses below cover alongside the fundamentals.

Watch for

Double materiality: a materiality-qualified rep tested under a materiality-qualified bring-down condition stacks two cushions; the materiality scrape exists to strip the first one back out when computing damages. And remember who stands behind the reps, all stockholders or some, jointly and severally or pro rata, decides what the words are worth. BC 41

See also: Covenants & Conditions, Indemnification, Glossary.

Covenants & Closing Conditions

Covenants are promises about conduct; conditions are tests for whether a party must close. Confusing the two, or the timing differences between conditions and termination rights, is how buyers end up trapped in deals and sellers end up sued. BC 63–71

The target's operational covenants hold the business in the ordinary course between signing and closing, preserving the organization the buyer priced. BC 64 The buyer's covenants center on efforts clauses for regulatory clearance, and the verbs are the negotiation: "commercially reasonable efforts," "reasonable best efforts," or a hell-or-high-water obligation that effectively guarantees antitrust clearance, with specific divestiture or litigation covenants and sometimes a reverse break-up fee if regulators kill the deal. BC 65–66

Conditions are the walk rights. The bring-down condition is the powerful one: it re-tests every undated representation at closing as if re-made, "20+ closing conditions rolled into one." BC 70, 254 The drafting question is the accuracy standard, "in all material respects" versus the MAE standard, and modern agreements often split the baseline reps from the fundamental reps, testing the former against an MAE standard and the latter strictly. BC 70–71

Alongside it ride the compliance-with-covenants condition, the no-injunction and no-litigation conditions, regulatory conditions, appraisal-rights thresholds, and key-employee conditions; "due diligence outs" and "financing outs" are resisted as free options. BC 42–43, 71

The MAC/MAE machinery deserves its own map. A front-door MAC is a standalone condition: no material adverse change since signing. A back-door MAC arises when the target's "absence of changes" rep (no MAC since the balance-sheet date) gets brought down to closing. They are not interchangeable: the back-door version measures from the earlier balance-sheet date, so a dismal quarter can be netted against a great one and never amount to a MAC; and the back-door version is qualified by the disclosure schedule, while a front-door condition is not. Sellers avoid giving both, by dating the MAC rep; buyers given the choice prefer the front door. BC 256–260

Finally, conditions are not termination rights. A failed condition excuses closing; it does not by itself end the agreement. A buyer facing a MAC may have to wait out the drop-dead date, during which the target's fortunes may recover and revive its obligation to close, unless the buyer negotiated an express MAC termination right, or can pair an undated MAC rep with the inaccuracy-based termination right (mind the cure period). BC 254–256

Watch for

The interaction traps: a rep excluded from the bring-down has no closing-condition force; a disclosure-schedule update may defuse a back-door MAC; and "material adverse effect" definitions live or die on their carve-outs (general economic conditions, industry effects, the deal's own announcement) and on whether carved-out causes count when they hit the target disproportionately.

See also: Representations & Warranties, Indemnification, Public M&A.

The Closing & the Closing Binder

Closing is the day the deal becomes real: signature pages are released, the purchase price is wired, the certificate of merger is filed, and ownership passes. The work that makes it look effortless is a checklist of dozens of deliverables assembled in advance and a funds flow reconciled to the dollar.

Begin with the gap closing fills. Most deals sign and close on separate days so the parties can clear antitrust, gather third-party consents, hold any stockholder vote, and arrange financing (see The Deal Process and Covenants & Closing Conditions). Closing is where every condition that survived that gap is finally tested and satisfied. In a simultaneous sign-and-close the two days collapse into one and the pre-closing covenants and many conditions fall away, but the deliverables do not: the parties still exchange the same certificates and move the same money, only all at once.

The instrument that runs the day is the closing checklist (the "closing agenda" or "responsibility schedule"): a living document, kept by lead counsel, listing every deliverable, who owes it, its status, and where its signature page stands. Read top to bottom, it is a map of the whole transaction. The deliverables fall into a few families. Authority and accuracy: a secretary's certificate attaching the charter, bylaws, and board and stockholder resolutions; an officer's (bring-down) certificate swearing the representations remain true and the covenants performed to the agreed standard, the contractual proof that the bring-down condition is met; and good-standing certificates from the states of incorporation and qualification.

Clearing the balance sheet: payoff letters from the existing lenders stating the exact figure to retire the target's debt and agreeing to release their liens on payment, paired with UCC-3 termination statements and other lien releases. Tax and regulatory: a FIRPTA certificate, the seller's non-foreign affidavit under IRC § 1445 that relieves the buyer of withholding, plus evidence that HSR and any other clearances are in hand. People and housekeeping: resignations of the departing directors and officers, any required 280G stockholder consent, and the executed ancillary agreements the deal rides on, the escrow agreement, employment and non-compete agreements, a transition services agreement on a carve-out, and a registration-rights agreement where stock is the consideration. On larger deals a legal opinion of the other side's counsel and a representation-and-warranty insurance binder round out the set.

Two mechanics deserve their own line. First, legal effectiveness. A merger does not close because the parties shake hands; it closes when the certificate of merger is filed with the secretary of state (DGCL § 251(c)), which fixes the effective time. A stock or asset deal instead turns on delivery of the stock powers or the bill of sale and the assignment instruments. Second, the money. The price moves on a funds flow memo, a line-by-line schedule of every source and use, the equity purchase price, the debt payoffs, the escrow funding, the transaction fees, and the net to each seller, with wire instructions attached. It is reconciled to the penny beforehand precisely so that on the day itself the only act left is sending the wires.

The choreography is now almost always remote. In the days before closing, each side's counsel circulates executed signature pages "in escrow," held and not released until everyone gives the word. On a pre-closing call the lawyers walk the checklist, confirm every deliverable is in hand and every signature page authorized for release, and agree the deal is ready. Closing itself is then a short call or email exchange: signatures are released, the certificate of merger is filed, the wires go out per the funds flow, and counsel confirm the funds landed. What was once a conference-room ritual of stacked binders is now a PDF release and a wire confirmation.

Afterward comes the closing binder, today usually a "closing set" delivered as an indexed PDF: the compiled, executed version of every document on the checklist, organized to the agenda and distributed to both sides as the transaction's permanent record. It is what a litigator, an auditor, or the team on the next financing pulls years later to prove what was signed and delivered. The binder closes the deal but not the file: the working-capital true-up is still to be measured, the indemnification survival clock has started, and the escrow waits for its release date.

Watch for

The closing binder is built backward from the agreement: every closing condition and every "deliver at closing" covenant should map to a line on the checklist, and a deliverable with no home in the agreement, or a condition with no deliverable, is a drafting error best caught before the closing call rather than on it. And confirm what actually makes the deal effective before the money moves: more than one closing has wired the price before the certificate of merger cleared the state, only to find the merger was not yet effective.

See also: The Deal Process, Covenants & Closing Conditions, Indemnification & Remedies, Purchase Price.

Indemnification & Remedies

Indemnification is the private deal's after-market: the negotiated machine by which the buyer recovers post-closing for inaccurate reps and breached covenants, bounded by survival periods, baskets, caps, and an escrow. BC 72–83

The mindsets frame everything: the buyer paid on the basis that the business is as represented and wants to be made whole; the sellers gave up the upside and want certainty that the proceeds stay theirs. BC 74 Indemnification is usually the exclusive remedy, with carve-outs for equitable relief and fraud; it covers rep breaches, covenant breaches, and negotiated special indemnities for known exposures (pending litigation, pre-closing taxes). BC 76, 79 Liability runs joint and several or pro rata among the sellers, and an indemnification escrow holds back part of the price as the collection source, often doubling as the practical cap. BC 78, 81 A stockholders' agent manages claims for a dispersed seller group. Public deals have none of this: the target's reps die at closing. BC 76

The limitations are the negotiation. Survival periods set a contractual statute of limitations, and the word "survive" alone has been held ambiguous (the Ninth Circuit's Western Filter decision), so sellers should say expressly that liabilities and remedies terminate on the survival date. BC 80, 249–250 Baskets come in two species, a true deductible (recover only the excess) or a tipping basket (cross the threshold and recover from dollar one), often with per-claim mini-baskets. BC 80 Caps bound aggregate exposure, typically tied to the escrow for ordinary reps with higher or uncapped tiers for fundamental reps, IP, and fraud. BC 81

Worked example (the $5m breach the section's close asks you to model). On a $100m deal, say the parties set a $500k basket (half a percent of the price), a $10m cap held in escrow, and 18-month survival. A $5m rep breach surfaces at month 12, inside survival. With a true deductible basket, the buyer recovers only the excess: $5m − $0.5m = $4.5m. With a tipping basket, crossing the $500k threshold unlocks the claim from dollar one, so the buyer recovers the full $5m. Either way the money is drawn from the escrow, and any loss above the $10m cap is the buyer's own, unless the breach hits a fundamental rep, IP, or fraud, which usually sit outside the cap. Move any one lever, the basket type, the cap, the survival clock, and the recovery moves with it, which is why these terms are priced against each other rather than one at a time.

The materiality scrape reads materiality qualifiers out of the reps when computing damages (and sometimes breach), neutralizing double materiality; buyers love it, sellers resist, and the Hotshot drafting courses below walk the variants.

Three drafting lessons from the nuggets deserve memorizing. First, the naked word "indemnify" has been read to cover only third-party claims (the California Zalkind case), so buyers should add "pay, compensate, and reimburse… regardless of whether such damages relate to a third-party claim" to capture first-party losses. BC 262–263

Second, the fraud exception to the limitations must be drafted narrowly: "in the event of fraud" can strip an innocent seller of the cap for someone else's fraud; black-letter law (the ABRY Partners line) only prevents a party from capping its own fraud. BC 263–264

Third, resist consequential-damages exclusions from the buy side: the term is jurisprudentially fuzzy (New York's high court split 4–3 on whether lost profits qualify), and sometimes consequential damages, like profits lost during a permit shutdown, are the only real damages. BC 264–265

Sandbagging is the capstone fight: may a buyer that knew a rep was false at signing close and claim anyway? Express pro- and anti-sandbagging clauses are both enforced; the danger zone is silence. Buyers long assumed Delaware was a "sandbagging state," but the Delaware Supreme Court's Eagle Force dicta put that in question, so buy-side counsel should insist on an express pro-sandbagging clause, drafted with the word "knowledge," not merely "no limitation by investigation." BC 82–83, 265–268 Per the ABA's 2023 private-target study, a plurality of filed deals include pro-sandbagging clauses while most of the rest stay silent, exactly the unstable middle the cases punish (cited as data; see Market Practice).

The seller-side mirror of all this is the non-reliance clause, the buyer's confirmation that it relied only on the express reps. Under Delaware law a good non-reliance clause kills fraud claims based on extra-contractual statements (the cooked projections in the data room), because the buyer represented it did not rely on them; without one, those claims survive the integration clause. BC 250–251

Watch for

Indemnification is a system, not a clause: survival × basket × cap × escrow × carve-outs × sandbagging × non-reliance interact, and a concession in one column is priced in another. Model the recovery path for a hypothetical $5m breach before signing off.

See also: Representations & Warranties, Purchase Price, Market Practice & Empirics.

Public M&A & Deal Protection

Public deals replace the private deal's indemnification machinery with disclosure, fiduciary duties, and deal protection: the no-shop, the superior-proposal out, match rights, and termination fees that police the gap between signing and the stockholder vote.

The structural differences start at the premise: public targets have dispersed stockholders who vote rather than sign, SEC proxy rules and the Williams Act apply, hostile acquisitions and interlopers are realistic, and the target's reps do not survive closing. BC 10 A public acquisition runs either as a one-step merger (proxy statement, stockholder vote) or a two-step acquisition (front-end tender offer, back-end merger). Equity awards must be converted or cashed out across options, RSUs, and the ESPP; a D&O tail insures the old board; appraisal rights under DGCL § 262 ride along; and the agreement typically grants specific performance and selects the Delaware Court of Chancery. BC 162–244

Deal protection is the buyer's answer to the target board's continuing fiduciary duties. The no-shop bars soliciting competing bids, subject to a fiduciary out: the board may engage with an unsolicited superior proposal and, under defined conditions, change its recommendation, after giving the buyer notice and a match right, and on payment of a termination fee if the deal dies.

The drafting trap is muzzling the board too tightly: a recommendation covenant that permits a change only for a superior proposal ignores the board's duty of candor, the "gold strike" scenario where the target becomes more valuable for reasons unrelated to any competing bid, and may be unenforceable against fiduciary duties. BC 274–275 The no-shop family (including forcing the vote and recommendation-change mechanics) is exactly what the three Hotshot No-Shop courses below cover.

Layer on the Delaware doctrine from the treatise side: Revlon duties when the company is for sale, Unocal review of defensive measures, and the modern cleansing framework for stockholder approval. That body of law is the Wachtell treatise's home turf, the anchor source below.

Watch for

MAE definitions in public deals are mostly carve-outs, and the litigated question is usually whether a carved-out cause hit the target disproportionately. And remember the timing asymmetry: between signing and the vote the target is "damaged goods" if the deal breaks, which is why boards extract reverse break-up fees and specific performance from buyers with financing or regulatory risk.

See also: Covenants & Conditions, Corporate Governance, Regulatory Gates.

Fiduciary Duties & the Sale Process

In a public deal the target's board is selling something it does not own, so its conduct is judged against fiduciary duties. The whole game is the standard of review: which of three lenses a Delaware court applies decides, almost by itself, whether the deal and the directors survive a challenge.

Begin with the duties. Directors owe a duty of care (to inform themselves and act deliberately) and a duty of loyalty (to act for the company and its stockholders, not themselves), with good faith and candor folded in. The business-judgment rule presumes a disinterested, informed board acted properly, and a court applying it will not second-guess the decision. Most of the litigation is therefore a fight about which standard applies, because the standard usually decides the outcome.

The middle tier is enhanced scrutiny, and it has two famous triggers. Under Unocal, when a board adopts defensive measures (a poison pill, say) it must show a reasonable threat and a response proportionate to it before deference returns. Under Revlon, once the company is being sold for cash or broken up so that control changes hands, the board enters "Revlon mode" and its duty narrows to getting the best price reasonably available; the court asks whether the process was reasonable, not whether it was perfect. Sitting beneath both is the lesson of Smith v. Van Gorkom: a board that approves a sale without informing itself breaches the duty of care, which is why boards run real processes and obtain a fairness opinion.

The top tier is entire fairness, where the board does not get the benefit of the doubt and must prove both a fair process and a fair price. It applies when a majority of the board is conflicted or, most importantly, when a controlling stockholder stands on the other side of the deal, the setting Weinberger v. UOP built the test for. Entire fairness is hard to win and expensive to litigate, so the practice is built around avoiding or escaping it.

Two doctrines provide the exits, and they are the practical heart of modern deal planning. Corwin v. KKR Financial holds that in a non-controller deal, approval by a fully-informed, uncoerced vote of the disinterested stockholders restores the business-judgment rule, which is why proxy disclosure is drafted so carefully: a disclosure gap can forfeit the cleanse. For controller deals, Kahn v. M&F Worldwide (MFW) offers the only clean path back to business-judgment review, but only if the deal is conditioned from the outset on both an empowered, independent special committee and an uncoerced majority-of-the-minority vote. Miss either prong, or bolt them on late, and the deal stays in entire fairness.

All of this drives the sale process itself. A board may run a broad auction or a single-bidder negotiation; either can satisfy Revlon if it is reasonable. A negotiated deal is often backstopped by a market check, sometimes an active go-shop window after signing rather than a pure no-shop, to test whether a better bid exists. Independent special committees wall off conflicted fiduciaries, and the deal-protection terms (the no-shop, fiduciary out, match right, and termination fee) are written to be strong enough to hold a deal together yet loose enough to respect these duties.

Watch for

Process is the product: Revlon asks for reasonableness, not the highest conceivable price, and a clean, well-documented process is the best defense. For anything touching a controller, treat MFW as all-or-nothing, both protections, in place before negotiations begin, or plan to litigate entire fairness. And never treat the proxy as boilerplate: under Corwin, the disclosure is what buys back business-judgment deference.

See also: Public M&A & Deal Protection, Valuation & Fairness Opinions, Corporate Governance.

Regulatory Gates

Three bodies of regulation gate most deals: antitrust premerger review under HSR, national-security review by CFIUS, and the securities laws whenever stock, notes, or even earn-out rights change hands.

The Hart-Scott-Rodino Act requires premerger notification for deals over the size thresholds and imposes a waiting period before closing; the deal chronology builds the HSR filing and clearance into the signing-to-closing gap, and one early reason to sign an LOI is to start that clock. BC 27, 36 The negotiation lives in the buyer's efforts covenant: from commercially reasonable efforts up through hell-or-high-water commitments, divestiture covenants, litigation covenants, and reverse break-up fees, the question is always who bears antitrust risk. BC 65–66 Remedies regulators accept divide into structural (divestiture) and behavioral commitments. In the public sample agreement, the buyer's obligations stop at a negotiated "Burdensome Condition," the ceiling on what it must give regulators. BC 162–244

CFIUS, the Committee on Foreign Investment in the United States, reviews acquisitions giving foreign persons control of (or certain rights in) U.S. businesses, with special teeth around critical technology, infrastructure, and data; cross-border deals build CFIUS conditions and covenants into the agreement, as Marvell/Aquantia did. BC 162–244

The securities laws reach M&A whenever consideration is not all cash at closing. Acquirer stock must be registered or fit an exemption (§ 4(a)(2), Regulation D, or the § 3(a)(10) fairness-hearing exemption), with resale restrictions following exempt issuances; promissory notes and escrow interests can be securities; and earn-out rights can be securities too, especially if transferable, handing sellers rescission rights if the buyer ignored registration. BC 38–39, 271 Public deals add the proxy rules and the Williams Act tender-offer regime. BC 10 The full securities-law architecture lives in Part II.

Watch for

Regulatory risk is priced, not avoided: the efforts verb, the burdensome-condition ceiling, the reverse break-up fee, and the outside date are one integrated trade. Read them together or misread them all.

See also: The Deal Process, Securities-Law Foundations, Public M&A.

Market Practice & Empirics

"What's market" is an empirical claim, and two study families answer it: the ABA's deal-points studies and the Buyer Power Ratio study, which indexes terms to relative bargaining power.

The ABA Private Target M&A Deal Points Studies (M&A Committee, Business Law Section) survey publicly filed private-target acquisition agreements and report the frequency of every major negotiated term: sandbagging clauses, materiality scrapes, basket types, cap sizes, survival periods, non-reliance clauses. The 2023 study is Tab 15 of the boot camp packet and is cited here as data only, the study is the ABA's copyrighted work, and its pages, charts, and tables are deliberately not reproduced anywhere in this encyclopedia. BC 281–348

The studies have known limitations, named by the boot camp faculty themselves: the sample is skewed, because only deals material to a public buyer get filed with the SEC, which systematically excludes the largest buyers' deals; and the one-size-fits-all averages lump $20m deals with $2b ones. BC 271–273 The Buyer Power Ratio study (ABA with SRS Acquiom, Tab 16) answers both: BPR = buyer market capitalization ÷ deal size, a proxy for negotiating leverage (a $50bn acquirer buying a $500m target has a BPR of 100; a $2bn buyer of a $1bn target, just 2, and the gap shows up in the terms each can demand), and terms correlate with it strongly. At BPRs below 10, buyers extract a 10b-5/full-disclosure rep roughly a third of the time; above 400, about three-quarters. BC 273, 349–374

Watch for

Climan's own caution: basing negotiating positions on market studies rather than logic is "paint by the numbers." BC 272 Use the data to calibrate asks and rebut "off-market" accusations, not to substitute for thinking about this deal's leverage.

See also: Indemnification (sandbagging, scrapes, consequential damages), Representations & Warranties.

UK M&A Practice

The English deal runs on different technology: warranties rather than surviving reps with indemnification, disclosure letters rather than schedules, heads of terms rather than LOIs, completion rather than closing, and W&I insurance as standard kit.

No taught entry yet; the Hotshot UK track below is the curriculum, and a UK section can be promoted to full taught status if the practice calls for it. The vocabulary differences alone, warranties and limitations on liability, disclosure letters, completion mechanics, are worth the first three courses.

Securities-Law Foundations

Two statutes carry the field: the Securities Act of 1933 governs the offer and sale of securities (register or find an exemption), and the Exchange Act of 1934 governs life afterward (reporting, proxies, tender offers, 10b-5).

The 1933 Act's § 5 default is that every offer and sale of a security must be registered with the SEC unless an exemption applies. That single sentence generates the whole practice: registered offerings (IPOs, follow-ons, shelf takedowns) on one side, and exempt offerings (§ 4(a)(2) private placements, Regulation D, Rule 144A institutional resales, Regulation S offshore deals) on the other. The registration statement's twin jobs are disclosure (the prospectus) and liability: § 11 strict-ish liability for material misstatements in the registration statement, § 12 for the prospectus, with the famous due-diligence defense for everyone but the issuer, which is why underwriters and their counsel investigate so hard (see Execution & Diligence).

Gun-jumping is the 1933 Act's communications discipline: outside the permitted windows, publicity that conditions the market for an offering can violate § 5, which is why quiet-period rules, free-writing-prospectus mechanics, and testing-the-waters provisions exist, and why marketing in a live deal runs through counsel.

The 1934 Act picks up once a company is public: periodic reporting (10-K, 10-Q, 8-K), the proxy rules, § 16 insider reporting, the Williams Act for tender offers, and Rule 10b-5's antifraud regime over everything. The reporting regime is also the input to capital raising: a seasoned issuer's Exchange Act file is incorporated by reference into its shelf, which is what makes follow-on offerings fast.

The instrument-level distinction worth internalizing early is debt versus equity offerings: equity sells ownership and trades on the issuer's story; debt sells a promise and trades on covenants, ratings, and yield, with its own market technology (indentures, trustees, high-yield covenant packages, the 144A market as the default venue for speed-sensitive debt).

Watch for

"Is it a security?" and "has there been an offer?" are both broader questions than instinct suggests, broad enough to capture earn-out rights and pre-deal publicity. When the answer is unclear, the practice is to behave as if the answer is yes.

See also: The IPO, Follow-Ons & Shelf, Regulatory Gates.

The IPO & Direct Listings

An IPO converts a private company into a reporting company and sells its first registered shares, through an S-1, an underwriting syndicate, a marketed roadshow, and a closing choreographed to the minute.

The deal runs in phases. Preparation: corporate cleanup (charter, governance, equity plans), financial statements to PCAOB standards, selecting underwriters, and the organizational meeting. Drafting: the Form S-1 registration statement, business, risk factors, MD&A, audited financials, built section by section in drafting sessions; emerging growth companies under the JOBS Act may submit confidentially and test the waters with institutional investors before going public with the filing. SEC review: comment letters and amendments, typically several rounds.

Marketing: the preliminary prospectus (red herring) and the roadshow, while the syndicate builds the book. Pricing: the underwriting agreement is signed at pricing, the registration statement goes effective, and the deal closes T+1/T+2 against delivery of comfort letters, legal opinions, and officers' certificates.

The underwriting agreement is the deal's contract: firm-commitment purchase at a discount, issuer reps mirroring the prospectus, indemnification for prospectus liability, lockups (typically 180 days for insiders), and closing conditions. The greenshoe (overallotment option) lets underwriters buy up to 15% more shares at the offering price to cover their short and stabilize aftermarket trading, the only SEC-sanctioned price support. Listing standards (NYSE/Nasdaq), FINRA's underwriting-compensation review, and state blue-sky preemption round out the regulatory frame.

The direct listing is the underwritten IPO with the underwriting removed: the company registers existing shares for resale, lists, and lets the exchange's opening auction discover the price. No firm-commitment syndicate, no fixed offering price, no lockup, no greenshoe; financial advisors replace underwriters, which raises its own § 11 questions (who is liable, and can a buyer trace shares to the registration statement). It suits well-known companies with no need for primary proceeds and a stockholder base that wants liquidity; exchange rules now also permit a primary-raise variant.

Watch for

The lawyer's IPO is mostly disclosure judgment under time pressure: what goes in risk factors versus MD&A, what's material, what the company can say outside the prospectus (gun-jumping again). The calendar is the discipline; everything maps back to effectiveness and pricing.

See also: Foundations, SPACs & De-SPACs, Execution & Diligence, Corporate Governance.

Underwriting & the Syndicate

Underwriting is how an offering actually gets sold: a syndicate of banks takes the securities off the issuer and resells them to investors, absorbing the placement risk in exchange for a spread. It is the same machine behind an IPO, a follow-on, and a bond deal, so it is worth learning once on its own.

Start with the commitment spectrum, because it allocates risk. In a firm-commitment underwriting, the norm for marketed U.S. equity and most bonds, the underwriters actually buy the entire offering from the issuer at a discount and resell it, so they, not the issuer, bear the risk that the deal does not sell. In a best-efforts deal the bank only agrees to try, taking no inventory risk; it is the structure behind an ATM program and weaker offerings. The bought deal (and its equity cousin, the overnight block trade) is the fast extreme: a single bank bids for the whole offering and buys it in one shot, taking all the risk to win the mandate, common for investment-grade bonds and follow-ons off the shelf.

The syndicate is the selling machine. The lead-left bookrunner runs the books, controls the timetable, and drives allocation; joint bookrunners share that work on larger deals; co-managers add distribution and research coverage; and a selling group can place shares without taking underwriting risk. The relationships are papered by the underwriting agreement between the syndicate and the issuer and the agreement among underwriters among the banks themselves. Position on the cover, who is "left," maps directly to league-table credit and fees, which is why it is negotiated hard.

The pay is the gross spread (the underwriting discount), the gap between what investors pay and what the issuer receives, and it splits three ways: a management fee to the bookrunners for running the deal, an underwriting fee that covers syndicate expenses and risk, and the selling concession, the largest piece, paid to whoever actually places the shares. Spreads vary enormously by deal type: the classic U.S. mid-cap IPO clusters near seven percent, while investment-grade bonds and large follow-ons price on a fraction of that.

Price and allocation come out of book-building. During the roadshow the bookrunner gathers indications of interest, builds a demand book, and prices off it; then it allocates, and allocation is discretionary, which makes it both a relationship tool and a historical source of abuse (the spinning and laddering scandals that FINRA rules now police). Underwriters also routinely oversell the deal by up to 15 percent, creating a short they cover through the greenshoe (the over-allotment option): if the stock trades up they exercise the option and buy the extra shares from the issuer, and if it trades down they buy in the open market, which supports the price.

That open-market buying is bounded by Regulation M, which bars the distribution participants from buying the offered security while the deal is being distributed, to stop them propping up the very price they are selling into. The narrow exceptions are stabilizing bids and syndicate covering transactions tied to the greenshoe; stabilization is the only price support the securities laws permit, and it must be disclosed. Read this entry as the connective tissue under the IPO, the shelf, and debt: the instrument changes, the syndicate machine does not.

Watch for

The spread is negotiable and deal-specific, so a "standard" number from one market misleads in another. And always read who sits lead-left, because that bank controls the book, the timetable, and the allocation, which is most of the real power in an offering. Where the underwriters take no risk (best-efforts, ATM), the investor protection shifts back onto disclosure and the diligence record.

See also: The IPO & Direct Listings, Follow-Ons, Shelf & ATMs, Debt Capital Markets, Execution & Diligence.

SPACs & De-SPACs

A SPAC is a shell that goes public on a promise: the sponsor raises cash into a trust, then has roughly two years to merge with a real business in a de-SPAC, the transaction that actually takes an operating company public.

The SPAC IPO sells units, typically a share plus a fraction of a warrant, at $10. Proceeds sit in a trust account invested in government securities; the sponsor buys founder shares (the promote, classically 20% of post-IPO equity for nominal consideration) and funds the deal's running costs with at-risk capital. Public stockholders hold a redemption right: when the business combination is put to a vote, each holder may take back its pro-rata share of the trust instead of riding along, whatever way it votes. Find no target in time and the SPAC liquidates, returning the trust.

The de-SPAC is where the real lawyering lives, because it is simultaneously a merger and an IPO substitute: a business-combination agreement with an operating target, a proxy/registration statement (often Form S-4) carrying IPO-grade disclosure about a company the market has never seen, and, in most deals, a concurrent PIPE to backstop redemptions and prove the valuation. Redemption math is the deal's physics: heavy redemptions drain the trust, so minimum-cash conditions, sponsor earnouts and promote forfeitures, and backstop financing are all negotiated against it.

The 2024 SEC rules (Release 33-11265) rebuilt the regime around one idea: a de-SPAC deserves IPO treatment. New Subpart 1600 of Regulation S-K requires granular disclosure of sponsor compensation, conflicts, and dilution; the target must generally be a co-registrant on the Form S-4/F-4, taking § 11 exposure; new Rule 145a deems a shell-company business combination a sale of securities to the shell's shareholders; Item 1609 disciplines projections; and the PSLRA forward-looking safe harbor is unavailable, restoring liability symmetry with the traditional IPO it replaced.

Watch for

Dilution is the SPAC's gravity: the promote, the warrants, and redemptions all transfer value from non-redeeming public holders, which is why the SEC made the issuer show the math. And diligence the target as if it were an IPO issuer, because after the 2024 rules it is one in substance and in liability.

See also: The IPO, PIPEs & Private Placements, Public M&A.

Follow-Ons, Shelf & ATMs

After the IPO, speed is the product. Seasoned issuers register securities "on the shelf" on Form S-3 and sell in takedowns measured in hours, in marketed follow-ons, overnight blocks, or a standing at-the-market dribble.

A follow-on offering is any registered equity raise after the IPO, marketed over days or "overnight" as a block. The machinery that makes it fast is the shelf: Form S-3 lets an eligible issuer (12 months of timely Exchange Act reporting, plus float or other tests) register securities for future issuance and incorporate its Exchange Act filings by reference, so the prospectus stays evergreen. A well-known seasoned issuer (WKSI, $700m+ float) files an automatic shelf effective on filing; the universal shelf registers debt, equity, and hybrids in one statement, so the instrument choice waits until the market window opens. Selling off the shelf is a takedown: a prospectus supplement, an underwriting or distribution agreement, and pricing, sometimes the same day.

The at-the-market (ATM) program turns the shelf into a faucet. Under an equity distribution agreement with one or more sales agents, the issuer sells newly issued shares into the existing trading market at prevailing prices, in amounts and at times it chooses, with no roadshow and no discount beyond the agent's commission. The legal maintenance is periodic: bring-down opinions, comfort, and diligence refresh on a calendar or at each "trigger" sale, which is why ATM programs reward issuers with clean, current Exchange Act files. REITs and steady repeat issuers run ATMs as standing infrastructure.

The exempt market runs parallel and has its own entries: PIPEs and private placements for equity sold without registration, and the 144A/Reg S debt machinery for speed-sensitive bonds. The practical rule everywhere: disclosure converges toward registered-deal quality even where the statute does not require it, because 10b-5 applies to every sale.

Watch for

Eligibility is a cliff: lose S-3 eligibility (a late 10-K, certain defaults) and the issuer drops from same-day takedowns to long-form registration. Capital-markets lawyers guard the issuer's reporting hygiene because financing speed depends on it.

See also: Foundations, PIPEs & Private Placements, Life as a Public Company.

PIPEs & Private Placements

A PIPE is a private investment in public equity: securities of a public company sold privately for speed and certainty, with a registration rights agreement promising the buyers a resale shelf afterward.

The architecture is the 1933 Act's exempt side. Section 4(a)(2) exempts transactions by an issuer "not involving any public offering"; Regulation D is its safe harbor, selling to accredited investors with restricted securities and Rule 144 holding periods as the price of skipping registration. Regulation S does the same work offshore. Diligence and disclosure discipline persist because Rule 10b-5 reaches every sale, registered or not.

The PIPE applies that machinery to a listed issuer. The classic execution: investors are wall-crossed under confidentiality, the deal is negotiated while the market is closed to the information, a securities purchase agreement signs, the transaction is announced, and closing follows in days. The buyers' liquidity comes from the registration rights agreement: the issuer files a resale registration statement on a deadline, with delay penalties. Instruments range from common at a discount through convertible preferred and warrants, which is where the structuring (and the dilution fights) live.

PIPEs are the financing of moments when the registered window is shut or certainty matters more than price: rescue capital in a downturn, the committed financing that backstops a de-SPAC, a strategic stake with governance terms attached. The discount and any board seat or standstill are the negotiated cost.

Watch for

Three traps recur: integration (a private placement too close to a public offering can collapse into it, now policed by the Rule 152 framework); the exchanges' 20% rule (NYSE and Nasdaq require stockholder approval for below-market private issuances of 20% or more of the outstanding shares); and MNPI hygiene for wall-crossed investors, who must be cleansed by the announcement or they cannot trade.

See also: SPACs & De-SPACs, Follow-Ons & Shelf, Foundations.

Debt Capital Markets

Debt capital markets sell promises. The instrument is a note governed by an indenture; the execution is either a registered takedown off the shelf or a Rule 144A/Regulation S placement that prices and closes in days.

The indenture is the constitution of a bond: the contract among issuer, trustee, and holders that carries the payment terms, covenants, events of default, and amendment mechanics (registered deals must also qualify it under the Trust Indenture Act). The notes' commercial terms ride on top: maturity and coupon, ranking and any guarantees, optional redemption with a make-whole premium during the protected period, and, in most modern deals, a change-of-control put at 101. Who can amend what is the quiet power map: money terms need each affected holder, most else a majority, which is what makes consent solicitations work.

Investment-grade execution is the shelf at its fastest: a WKSI takedown priced off the desk in a morning, documentation thin because the credit is strong. IG covenants protect ranking, not cash flow: a negative pledge over liens, a sale-leaseback limit, a merger covenant, and little else, the working contrast with the high-yield package. Commercial paper handles the short end through standing programs. Medium-term note (MTN) programs apply program logic to the middle: standing documentation, a distribution agreement with dealers, and takedowns sized to reverse inquiry.

Rule 144A/Regulation S execution is the unregistered parallel track and the default for speed-sensitive and high-yield credit: the issuer sells to initial purchasers who immediately resell to qualified institutional buyers (144A) and offshore (Reg S), on an offering memorandum built to registered-deal disclosure standards but never reviewed by the SEC. The 10b-5 negative-assurance letter and full diligence ride along, because antifraud liability does. Securitization runs the same program logic against asset pools rather than corporate credit; it is its own field, and the SIFMA primers are the fastest map of it.

Watch for

Ask first what market the deal is in, because the answer sets the documents, the timeline, and the covenants: registered IG off the shelf, 144A high yield on an OM, or a program takedown. Then read the redemption and amendment provisions before anything else; they decide who holds the options the rest of the contract only describes.

See also: High-Yield Covenants, Liability Management, Lending & Finance.

High-Yield Covenants

High-yield bonds finance leveraged credits, and the covenant package is the product: incurrence-based restrictions that police debt, liens, dividends, and asset sales while leaving daily operations alone.

The structural idea distinguishes the market. Bank loans carry maintenance covenants, tested every quarter whether or not the borrower acts; high-yield bonds carry incurrence covenants, tested only when the issuer does something, borrows, pays a dividend, sells assets, merges. Between actions the issuer is free, which is why a leveraged issuer can live under a high-yield indenture for a decade. The package travels under names worth knowing cold: limitation on indebtedness (borrow only through a ratio test or enumerated baskets), limitation on restricted payments (dividends, buybacks, and junior prepayments paid from a builder basket that grows with retained earnings), limitation on liens and anti-layering, asset sales (proceeds reinvested or offered back to holders), affiliate transactions, and the change-of-control put at 101.

The covenants read as broad prohibitions followed by definitions and baskets that give most of the ground back; the deal's real terms live in the exceptions. And the definitional layer is where value moves: EBITDA with its negotiated add-backs sets every ratio, so an aggressive definition loosens the entire package at once. The execution wrapper is the 144A/Reg S machinery: an offering memorandum, a purchase agreement with initial purchasers, a roadshow measured in days, and redemption economics (non-call period, call schedule, equity clawback, make-whole) negotiated against the calendar.

Watch for

Never read a covenant without its definitions; the prohibition is boilerplate and the basket is the deal. When the analysis matters, build the capacity math: how much debt, and how much value out the door, the package actually permits today.

See also: Debt Capital Markets, Lending & Finance, Restructuring.

Convertible Notes & Equity-Linked

A convertible note is a bond carrying an embedded call option on the issuer's stock: the holder trades coupon for upside, the issuer trades potential dilution for cheap money, and the whole package prices in an afternoon.

The economics are a straight swap. The issuer pays a coupon well below its straight-debt cost because the holder also receives the right to convert into shares at a conversion price set at a premium (commonly 25–40%) over the stock price at pricing. If the stock never reaches the premium, the holder owned a cheap bond; if it does, conversion delivers the upside. The terms that do the work: the conversion rate and its anti-dilution adjustments, dividend protection, and a make-whole fundamental change table that compensates holders with extra shares if the issuer is acquired before maturity.

Settlement method is the structural decision: physical (all shares), cash, or the now-standard flexible settlement, principal in cash with the excess in shares, which softens dilution and drives the accounting and the diluted share count. Issuers then manage the residual dilution with a capped call or call spread bought from banks' derivatives desks alongside pricing, synthetically lifting the effective conversion premium; pairing the offering with a concurrent stock buyback is the market's "happy meal." Execution is typically an overnight 144A deal sold heavily to convertible-arbitrage funds, whose delta-hedging the issuer's stock absorbs at announcement.

Watch for

The convert is two trades stapled together: read the indenture's conversion mechanics and the capped-call confirmations as one economic package, because the derivative's terms (cap price, expiration mechanics, unwind on early conversion) decide what the issuer actually pays for dilution protection.

See also: Debt Capital Markets, PIPEs & Private Placements, Capitalization Table.

Liability Management

Liability management reshapes outstanding debt without waiting for maturity: tender offers retire it for cash, exchange offers swap it for new paper, and consent solicitations rewrite the covenants it lives under.

The toolkit runs from quiet to loud. Open-market repurchases buy bonds at a discount with no offer at all, subject to MNPI discipline. A cash tender offer invites all holders to sell at a price, often structured with an early tender premium and a waterfall across series. An exchange offer swaps old notes for new ones, registered or exempt: Section 3(a)(9) exempts an issuer's exchange with its existing holders where no one is paid to solicit, which makes same-issuer exchanges fast; third-party or solicited deals need registration or 4(a)(2)/144A. A consent solicitation pays holders to amend the indenture, alone or stapled to an exchange, where exit consents have tendering holders vote covenants away on their way out the door, pressuring holdouts to come along.

The rules of the road come from the Exchange Act's tender-offer regime: Regulation 14E applies to debt tenders, with its 20-business-day baseline, extension requirements on price changes, and prompt-payment rule; SEC staff no-action relief permits five-business-day abbreviated tenders for non-convertible investment-grade and certain other debt meeting strict conditions (any-and-all, immediate payment, no exit consents). Equity self-tenders and third-party bids pick up the heavier 13e/14d machinery from Public M&A. In distressed credits the same instruments turn aggressive, the uptier and drop-down exchanges of the restructuring world; the line between a market-clearing exchange and a coercive one is where the litigation lives.

Watch for

Structure dictates timeline: the same economic deal can be a 5-day tender, a 20-day exchange, or a months-long registered offer depending on the instruments and exemptions chosen. Map the consent thresholds first, because what a majority can amend (and what needs every holder) decides whether the transaction can be done over objectors at all.

See also: Debt Capital Markets, High-Yield Covenants, Public M&A.

Life as a Public Company

Once the offering closes, the company lives under the Exchange Act: periodic reports on a fixed calendar, 8-Ks measured in business days, proxy season every spring, insider filings measured in hours, and a disclosure discipline that never sleeps.

Periodic reporting is the spine: the annual 10-K and quarterly 10-Qs on deadlines set by filer status, and the Form 8-K for enumerated current events, most due within four business days of the trigger. Sarbanes-Oxley wires accountability into the system: CEO/CFO certifications, disclosure controls and procedures, and internal control over financial reporting under § 404. The reporting calendar is also the financing calendar, since timely filing keeps the shelf alive and the comfort letters clean.

Proxy season runs the annual meeting through Schedule 14A: director elections, say-on-pay, auditor ratification, shareholder proposals under Rule 14a-8, and the executive-compensation disclosure (CD&A and the tables) that draws the most reading. Insiders live on a faster clock: Section 16 officers, directors, and 10% holders file Form 4s within two business days of trading and disgorge short-swing profits under § 16(b); trading happens inside windows, under insider-trading policies, and increasingly through Rule 10b5-1 plans with mandatory cooling-off periods. Regulation FD completes the discipline: no selective disclosure of material nonpublic information to analysts or holders without simultaneous public dissemination.

The exchanges add the governance layer: NYSE and Nasdaq listing standards require majority-independent boards, independent audit, compensation, and nominating committees, and stockholder approval of equity plans and the 20%+ private issuances. This is the standing client relationship of a capital-markets practice: the offerings are episodic, the reporting, governance, and compliance counseling are continuous.

Watch for

The 8-K items are specific and the clock is four business days, so when an event lands, read the item text rather than reasoning from materiality instinct; some triggers are bright-line. And treat Reg FD as an architecture question: build the disclosure calendar and the spokesperson list so the violation cannot happen casually.

See also: Foundations, Follow-Ons & Shelf, Corporate Governance.

Execution & Diligence

Execution craft is what underwriters' counsel sells: the due-diligence record that earns the § 11 defense, the comfort letter and circle-up that tie every number to the auditors, and a closing where forty documents arrive in the right order.

Due diligence for a securities offering differs from M&A diligence in purpose: it is built to establish that, after reasonable investigation, the non-issuer participants had reasonable ground to believe the disclosure was true, the statutory defense to § 11 liability. It runs as documentary diligence, management and auditor sessions, and bring-down calls at pricing and closing.

The comfort letter is the auditors' letter to the underwriters giving negative assurance on the financial data and "ticking and tying" specified numbers; the circle-up is the marked prospectus identifying every number the letter covers. The regulatory layer for the financial statements themselves, what financials a registration statement needs, acquired-business financials under S-X 3-05, pro formas under Article 11, aging and staleness rules, is codified in the SEC staff's Financial Reporting Manual, the desk reference for every registration-statement financial-statements question.

Closing a registered offering is choreography: effectiveness, pricing terms, the underwriting agreement, then at closing the opinions (corporate, 10b-5 negative assurance), officers' and secretary's certificates, the comfort bring-down, good-standings, DTC mechanics, and funds flow. The skill is anticipating which document breaks first.

Watch for

Diligence is a defense only if the record shows it happened: contemporaneous notes, signed-off circle-ups, documented bring-downs. Build the file as if a § 11 plaintiff will read it, because that is precisely the scenario it exists for.

See also: The IPO, Follow-Ons & Shelf.

Private Equity

Private equity buys companies with funds raised from limited partners, improves or re-levers them, and sells inside a fund's life cycle; for the deal lawyer it means a financial buyer with its own structures, papers, and incentives.

The architecture: a sponsor (the management company and its GP entities) raises a fund from LPs; the fund commits equity to deals through equity commitment letters, borrows the rest (see Lending & Finance), and acquires targets through a stack of holding companies (see Parent Aggregator). Management is kept and re-incentivized through rolled equity and incentive units; returns are measured in MOIC and IRR. PE M&A differs from strategic M&A in predictable ways: all-cash consideration, financing conditions and commitment papers, speed-to-signing as a bid weapon, and exit thinking from day one. BC 12

See also: Deal Structures & Tax, Indemnification.

Parent Aggregator

A parent aggregator is a holding company that pools all the equity capital in a buyout, fund and co-investors, blocked investors, and management’s rolled equity, into one parent entity sitting atop the acquisition structure.

In a typical private-equity “corporate stack,” the aggregator, often called the TopCo or an LLC/LP “AggregatorCo,” is the entity whose equity every investor actually holds. It owns the lower holding companies that carry the debt and acquire the target. Aggregating into one parent simplifies governance and lets different kinds of capital, fund LPs, co-investors, blocker corporations for non-US or tax-exempt investors, and management rolled equity, sit side by side in a single capital structure. The multi-tier stack also isolates risk: debt placed at a lower entity stays contained there if the business underperforms.^[9][10]

Watch for

Where rolled and management equity is issued, at the aggregator versus at a flow-through operating entity in blocker deals, changes the tax leakage and the economics. The layering exists for debt placement and risk isolation, not for show.

See also: Rolled Equity, Capitalization Table.

Rolled Equity

Rolled equity is the portion of sale proceeds that sellers or management reinvest into equity of the new (buyer’s) structure instead of cashing out fully.

In a buyout, owners and management “roll over” part of their equity value, commonly 10–40%, into the acquirer’s aggregator or TopCo, taking new equity rather than all cash. This aligns management with the sponsor’s upside, the “second bite of the apple” at the next exit, and reduces the cash the sponsor must fund at closing. Structured correctly, the roll is often tax-deferred: treated as a contribution into the new entity rather than a fully taxable sale.^[9] The rolled stake then appears on the new cap table alongside the sponsor’s.

Example

A founder sells the company for $100M, rolls 20% ($20M) into the sponsor’s TopCo, and takes $80M in cash. If the next exit doubles the equity, the rolled $20M stake is worth roughly $40M, a return often measured in MOIC.

Watch for

Whether the roll is genuinely tax-deferred depends on the structure; rolled equity may sit junior to the sponsor’s preferred; and leaver and vesting terms can claw it back if management departs.

See also: Parent Aggregator, Capitalization Table, MOIC.

MOIC — Multiple on Invested Capital

MOIC is total value returned divided by capital invested: how many times your money came back, ignoring time.

The formula is (realized value + unrealized value) / invested capital. A 2.0x means the money doubled; 1.5x is a 50% gain. It is a simple, time-blind measure of absolute value creation, quoted gross (at the deal level) or net (after fees and carry); the fund-level cousin is TVPI. Because it ignores time, MOIC is almost always read alongside IRR.^[11][12]

Example

Invest $50M, exit for $150M → MOIC = 3.0x.

Watch for

It ignores time entirely: a 2.0x in one year and a 2.0x in ten years look identical but are wildly different returns. MOIC says nothing about speed.

See also: IRR.

IRR — Internal Rate of Return

IRR is the annualized discount rate that makes the net present value of all an investment’s cash flows equal to zero: the time-weighted return per year.

Unlike MOIC, IRR captures both the size and the timing of cash flows, so it rises when money comes back faster. It is sensitive to early distributions and to interim valuations, and is quoted gross or net. The two metrics are complementary: MOIC measures how much value was created, IRR how efficiently in time.^[11]

Example

$50M in, $150M out after five years with no interim flows → MOIC 3.0x. IRR is just the annual rate that compounds $50M into $150M over those five years: (150 ÷ 50)^1/5 − 1 ≈ 24.6%. Pull the same 3.0x forward to three years and the rate jumps: (150 ÷ 50)^1/3 − 1 ≈ 44.2%. Identical money multiple, very different IRR, because IRR counts the waiting and MOIC does not.

Watch for

IRR can be flattered by timing: early distributions and subscription-line financing inflate it, and a high IRR on a tiny or very fast deal can still return little cash. Always read it next to MOIC.

See also: MOIC.

Venture Capital

Venture practice is preferred-stock deal-lawyering on industry-standard documents: term sheet, charter, stock purchase agreement, investor rights, voting, and ROFR/co-sale, with the economics living in the preferences and the cap table.

A priced round issues preferred stock whose charter carries the economics (liquidation preference, dividends, anti-dilution, conversion) and control terms (protective provisions, board seats); the NVCA model documents standardize the suite, and their drafters' footnotes are a free course in why each clause exists. Early money often arrives as convertible notes or SAFEs that convert at the next round, with caps and discounts doing the pricing. The arithmetic, price per share, pro-rata rights, preference waterfalls, note conversion, runs through the cap table.

See also: Capitalization Table, Equity Awards, Corporate Governance.

Capitalization Table

A capitalization table (cap table) is the ledger of who owns what in a company: every share, option, and convertible, by holder and class.

It tracks ownership and the claims on equity value, founders, investors by round and class, the option pool, warrants, and convertibles such as SAFEs and notes, usually on a fully-diluted basis. It is what you use to compute ownership percentages, the dilution a new round causes, and the payout waterfall at exit. “Fully diluted” counts all options and convertibles as if exercised or converted, and the table is tracked pre-money and post-money around each financing. The pool that feeds equity awards lives here, and so does any rolled equity from a buyout.

Watch for

A pre-money option-pool expansion dilutes founders, not the incoming investor; convertibles can create surprise dilution when they convert; and the percentage you are quoted at signing may differ from your fully-diluted percentage.

See also: Equity Awards, Rolled Equity.

Lending & Finance

Debt finance is the other half of every leveraged deal: the credit agreement and its covenants, the collateral package that secures it, and the closing mechanics that move the money.

The map: a loan starts with commitment letters and term sheets, papers into a credit agreement (revolvers, term loans A/B, often syndicated across lenders), and is secured through guaranties from affiliates and a collateral package, security and pledge agreements creating security interests, perfected by UCC financing statements. The credit agreement's engine room is covenants and events of default: affirmative, negative (debt, liens, restricted payments), and financial maintenance covenants, with leveraged-loan and high-yield packages differing in well-mapped ways. Exits run through payoff letters and lien releases. In the capital-markets adjacency, leveraged lending and high-yield bonds are siblings: same credits, different documents and markets.

See also: Private Equity, Follow-Ons, Shelf & ATMs.

Corporate Governance

Governance is the operating system every deal runs on: the charter and bylaws, the board and officers, the approvals and certificates, and, for public companies, the fiduciary-duty caselaw and disclosure regime layered above them.

The corporate mechanics, incorporation, charters and bylaws, board and stockholder approvals, written consents, officers' and secretary's certificates, form checks, franchise taxes, are the junior corporate lawyer's daily bread and the Hotshot track below. Above them sits the Delaware fiduciary layer (care, loyalty, oversight; the business-judgment rule and its exceptions) and, for public companies, proxy season, annual reports, and board hot topics. Good-to-know depth, not the working expertise; the anchors below keep it current.

See also: Public M&A & Deal Protection, Securities-Law Foundations.

Commercial Contracts & Drafting

The "boilerplate" at the back of every agreement is a set of loaded weapons: assignment, indemnification, limitation of liability, survival, entire agreement, notice. The drafting craft is knowing which ones fire and when.

The Hotshot track below walks the standard provisions clause by clause; the M&A nuggets in Part I supply the cautionary tales (the ambiguity of "indemnify" and "survive," non-reliance clauses versus the entire-agreement clause, third-party-beneficiary conflicts BC 270). The house entry below, the Master Vendor Agreement, is the commercial-contracts pattern in the wild.

See also: Anatomy of the Agreement, Master Vendor Agreement.

Master Vendor Agreement

A Master Vendor Agreement (MVA) is a single overarching contract that fixes the standing terms between a buyer and a vendor once, so every later purchase runs on those terms instead of being renegotiated.

The body of the agreement holds the terms that rarely change: payment, liability, intellectual property, confidentiality, warranties, termination, and governing law. The specific, changing details of each engagement live in subordinate documents, Statements of Work (SOWs), purchase orders, or service orders, that incorporate the master by reference. The purpose is leverage and speed: negotiate the hard terms once, then transact quickly. Closely related instruments, often used loosely as synonyms, are the Master Services Agreement (services rather than goods) and the master supply or purchase agreement.

Key terms

Order of precedence; Statement of Work (SOW); limitation of liability (the cap, and the carve-outs that sit outside it, such as IP infringement, breach of confidentiality, and gross negligence); indemnification; the consequential-damages waiver; IP ownership (work-for-hire versus license); confidentiality; data processing addendum (DPA); insurance requirements; term and termination (for cause versus for convenience, and survival); assignment.

Example

A company signs one MVA with an IT services vendor, then issues a fresh SOW for each project every quarter. Each SOW references the master’s liability cap and IP terms rather than re-fighting them.

Watch for

The clause to read first is order of precedence. When an SOW conflicts with the master, which controls? The safe default is that the master governs unless an SOW expressly amends a named section; otherwise a salesperson’s order form can quietly gut the negotiated liability cap. Confirm too which losses sit outside the cap and how the consequential-damages waiver reads.

See also: Commercial Contracts & Drafting.

Equity Awards

An equity award is compensation paid in company ownership rather than cash, used to attract talent and align the recipient’s incentives with the company’s value over time.

The term is an umbrella over several instruments that differ mainly in when you are taxed and what you actually own. Stock options grant the right to buy shares later at a fixed strike (exercise) price; ISOs carry favorable tax treatment but are employee-only and capped, while NSOs/NQSOs are more flexible and used for contractors and advisors. An option is a right to buy, not ownership yet. Restricted stock (an RSA) is actual stock granted now but forfeitable if you leave before vesting; you own it at grant, and it is the instrument on which a Section 83(b) election can be made. RSUs are only a promise to deliver shares or cash at vesting, so you own nothing until settlement and generally have nothing to make an 83(b) election on.^[6]

Key terms

Strike / exercise price; ISO versus NSO; RSA versus RSU; vesting schedule (commonly four years with a one-year cliff, then monthly); single- versus double-trigger acceleration; the 409A valuation that sets the strike for private stock; dilution on the capitalization table; the post-termination exercise window (often only 90 days).

Example

A new hire receives 40,000 NSOs at a $1.00 strike, vesting over four years with a one-year cliff. After year one, 10,000 options vest and become exercisable; the rest vest monthly thereafter.

Watch for

The 90-day post-termination exercise window is a notorious trap; a strike mispriced below 409A fair value creates tax penalties; and RSUs cannot be 83(b)-elected.

See also: Section 83(b) Election, Capitalization Table, Rolled Equity.

Section 83(b) Election

An 83(b) election is a filing that tells the IRS to tax you now, on the value of restricted stock at grant, rather than later as it vests.

Under the default rule of § 83(a), stock received for services that is subject to a substantial risk of forfeiture is taxed as it vests, on the spread between its value then and what you paid, all as ordinary income. For fast-appreciating stock that means rising ordinary-income bills across the whole vesting period. The election under § 83(b) flips that: within 30 days of grant you elect to be taxed now on the grant-date spread, often near zero at a brand-new company. Future appreciation is then deferred and converts to capital gain, and the capital-gains holding period starts at grant. It is a bet that the stock appreciates, bought with a small or zero tax now and the risk that you prepaid tax on stock you never keep. The election applies to restricted stock, not to RSUs.

Filing

The 30-day deadline runs from the transfer or grant date, with no extensions. You may file by certified mail (return receipt) or online through the IRS’s DMAF portal using Form 15620 and an ID.me login; use only one method. A copy must still go to the company, though since 2016 it is no longer attached to your tax return.^{[1][2][3][4][5][8]}

Example

A founder buys 1,000,000 shares of restricted stock at $0.0001 ($100 total), equal to fair value at grant. Filing 83(b) reports about $0 of income now; selling years later at $5/share produces capital gain rather than ordinary income recognized at each vesting date.

Watch for

Missing the 30-day window forecloses the election entirely, and RSUs are generally ineligible. The online portal historically capped quantity and decimal places, a limit the IRS fixed in October 2025 to four decimal places and roughly 99,999,999.99 shares.^[7] The IRS’s own plain-language guidance and the paper form still lead with mailing, so many advisers mail certified for a provable record.

See also: Equity Awards, Capitalization Table.

OSHA & the OSH Act

OSHA is both the federal agency and, by shorthand, the 1970 statute (the OSH Act) that set and enforce minimum workplace safety and health standards for most private-sector employers.

The Occupational Safety and Health Administration sits in the U.S. Department of Labor and was created by the Occupational Safety and Health Act of 1970. It writes safety and health standards, inspects workplaces, and issues citations and penalties. It covers most private-sector employers across the 50 states, the District of Columbia, and the territories, either directly or through an OSHA-approved State Plan that must be “at least as effective” as the federal program.^[13][16] Its broadest tool is the General Duty Clause, § 5(a)(1), which requires every employer to furnish a workplace “free from recognized hazards” likely to cause death or serious physical harm even where no specific standard applies; § 5(b) requires employees to comply with applicable standards.^[13]

Key terms

General Duty Clause (§ 5(a)(1)); specific standards (hazard communication, PPE, fall protection, lockout/tagout); the hierarchy of controls (engineering → administrative → PPE); recordkeeping (the OSHA 300 log); inspection, citation, and abatement; State Plans; whistleblower and anti-retaliation protection (§ 11(c)).

Watch for

To use the General Duty Clause, OSHA must prove a four-part test: a hazard existed, the employer or its industry recognized it, it was likely to cause serious harm, and a feasible means of abatement existed. State-Plan states may impose stricter rules, and § 11(c) bars retaliation against workers who report.

Litigation

The litigation track: pleadings, discovery, depositions, motion practice, written advocacy, experts, and trial.

Restructuring & Bankruptcy

Chapter 11 and the restructuring toolkit, the downside case of every leveraged structure in Parts I–III.

Finance & Accounting

Financial statements, accounting concepts, and valuation, the numeracy layer under MD&A, comfort letters, and every purchase price adjustment.

The Business of Law

How firms and clients actually work: economics, staffing, and the service business around the documents.

AI & Legal Tech

The tooling layer: AI in practice, legal tech, and what changes when the documents draft themselves.

Professional Skills

The craft around the craft: communication, workflow, and working with senior lawyers and clients.

Microsoft Word

Word at the level deal documents demand: styles, numbering, cross-references, comparisons.

Microsoft Excel

Excel for lawyers: formulas, lookups, models, and large data sets, the working-capital schedule will be in one.